View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 27, 2020

Australian researchers to trial BCG vaccine for Covid-19

Researchers at the Murdoch Children’s Research Institute in Australia are set to conduct a randomised, multi-centre clinical trial to test the use of tuberculosis vaccine BCG against Covid-19.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Researchers at the Murdoch Children’s Research Institute in Australia are set to conduct a randomised, multi-centre clinical trial to test the use of tuberculosis vaccine BCG against Covid-19.

The BRACE trial is intended for healthcare workers. It is based on previous study findings that BCG decreases the level of virus in patients infected by viruses similar to SARS-CoV-2.

Murdoch Children’s Research Institute director Kathryn North said: “This trial will allow the vaccine’s effectiveness against Covid-19 symptoms to be properly tested, and may help save the lives of our heroic frontline healthcare workers.”

The controlled trial is expected to enrol approximately 4,000 healthcare workers at hospitals across Australia, including the Melbourne Campus’ Royal Children’s Hospital.

BCG will be assessed for its ability to mitigate the prevalence and severity of Covid-19 symptoms.

More than 130 million babies currently receive the BCG vaccination for tuberculosis each year. The vaccine is said to enhance ‘frontline’ immunity.

The improved immunity is expected to provide the time required to develop and validate a specific vaccine for Covid-19 infection.

The BRACE study is based on an existing trial at the institute, which led to human ethics approvals. The existing trial is being conducted at sites across Australia.

North added: “Using rapidly sourced and immediately deployable funds, we will be relentless in our pursuit of preventions and treatments for this unprecedented pandemic.

“These trials will allow the rapid advancement of the most promising candidates to clinical practice, giving us the most number of shots on goal against Covid-19 as possible.”

Trials of potential vaccine candidates for Covid-19 are already underway in the US and China.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena